Person:
Hong, Xin

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Hong

First Name

Xin

Name

Hong, Xin
Author's Publications: search.filters.isAuthorOfPublication.f59efebf-0ff4-4d6a-87d6-48d8ded8a479

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
    (National Academy of Sciences, 2018) Hong, Xin; Sullivan, Ryan; Kalinich, Mark; Kwan, Tanya Todorova; Giobbie-Hurder, Anita; Pan, Shiwei; LiCausi, Joseph A.; Milner, John D.; Nieman, Linda T.; Wittner, Ben; Ho, Uyen; Chen, Tianqi; Kapur, Ravi; Lawrence, Donald; Flaherty, Keith; Sequist, Lecia; Ramaswamy, Sridhar; Miyamoto, David; Lawrence, Michael; Toner, Mehmet; Isselbacher, Kurt; Maheswaran, Shyamala; Haber, Daniel
    A subset of patients with metastatic melanoma have sustained remissions following treatment with immune checkpoint inhibitors. However, analyses of pretreatment tumor biopsies for markers predictive of response, including PD-1 ligand (PD-L1) expression and mutational burden, are insufficiently precise to guide treatment selection, and clinical radiographic evidence of response on therapy may be delayed, leading to some patients receiving potentially ineffective but toxic therapy. Here, we developed a molecular signature of melanoma circulating tumor cells (CTCs) to quantify early tumor response using blood-based monitoring. A quantitative 19-gene digital RNA signature (CTC score) applied to microfluidically enriched CTCs robustly distinguishes melanoma cells, within a background of blood cells in reconstituted and in patient-derived (n = 42) blood specimens. In a prospective cohort of 49 patients treated with immune checkpoint inhibitors, a decrease in CTC score within 7 weeks of therapy correlates with marked improvement in progression-free survival [hazard ratio (HR), 0.17; P = 0.008] and overall survival (HR, 0.12; P = 0.04). Thus, digital quantitation of melanoma CTC-derived transcripts enables serial noninvasive monitoring of tumor burden, supporting the rational application of immune checkpoint inhibition therapies.